Copyright
©2007 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 28, 2007; 13(40): 5343-5350
Published online Oct 28, 2007. doi: 10.3748/wjg.v13.i40.5343
Published online Oct 28, 2007. doi: 10.3748/wjg.v13.i40.5343
Figure 1 Cumulative recurrence rates after curative treatment of HCC.
A: Rates of first recurrence compared between IFN and non-IFN groups, showed no significant difference (P = 0.153); B: Rates of second recurrence compared between IFN and non-IFN groups. The second recurrence rate for the IFN group was lower than that for the non-IFN group (P = 0.022).
Figure 2 Cumulative recurrence rates according to SVR to IFN therapy after curative treatment of HCC.
A: Rates of first recurrence compared among SVR, non-SVR and non-IFN groups. The rate of first recurrence of HCC in the SVR group was significantly lower than in the non-SVR and non-IFN groups (P = 0.002, P = 0.016, respectively). No significant difference in first recurrence rate was seen between the non-SVR and non-IFN groups (P = 0.381); B: Rates of second recurrence compared among the three groups. Second recurrence of HCC was suppressed in the SVR group compared with the non-SVR and non-IFN groups (P = 0.0037, P = 0.0019, respectively), and to a more pronounced degree than for the first recurrence rate. No significant difference in second recurrence rate was seen between the non-SVR and non-IFN groups (P = 0.90).
Figure 3 Cumulative survival rates after curative treatment of HCC.
A: Comparison of cumulative survival rates in the IFN and non-IFN groups. The cumulative survival rate was significantly higher in the IFN group than in the non-IFN group (P = 0.039); B: Comparison of cumulative survival rates in the SVR, non-SVR and non-IFN groups. Although no significant overall difference was found between the SVR and non-SVR groups (P = 0.538), the SVR group had a particularly high survival rate compared with the non-IFN group (P = 0.029).
Figure 4 Influence of IFN therapy after curative treatment of HCC on Child-Pugh scores.
IFN-treated patients were less likely to show deterioration of hepatic function. In particular, liver function scores in the SVR group were significantly better preserved than in the non-IFN group (P = 0.003). Median observation time was 59.8 mo in the SVR group, 45 mo in the non-SVR group, and 51.8 mo in the non-IFN group.
- Citation: Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Effects of a 24-week course of interferon-α therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007; 13(40): 5343-5350
- URL: https://www.wjgnet.com/1007-9327/full/v13/i40/5343.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i40.5343